Kamada (NASDAQ:KMDA) Downgraded by Wall Street Zen to Hold

Kamada (NASDAQ:KMDA) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday.

A number of other research analysts have also recently issued reports on KMDA. Benchmark reiterated a “buy” rating on shares of Kamada in a research note on Thursday, March 12th. Stifel Nicolaus set a $11.00 target price on shares of Kamada in a research note on Wednesday, March 11th. Finally, Weiss Ratings upgraded shares of Kamada from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday, May 15th. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Kamada currently has an average rating of “Buy” and an average target price of $12.00.

Kamada Trading Up 0.1%

NASDAQ:KMDA opened at $7.83 on Friday. Kamada has a 1 year low of $6.50 and a 1 year high of $9.35. The firm has a 50 day moving average of $8.29 and a 200-day moving average of $7.92. The stock has a market capitalization of $450.30 million, a P/E ratio of 22.37, a price-to-earnings-growth ratio of 0.72 and a beta of 0.86.

Kamada (NASDAQ:KMDA) last posted its earnings results on Thursday, May 14th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.05). Kamada had a net margin of 11.21% and a return on equity of 7.73%. The firm had revenue of $45.24 million during the quarter, compared to the consensus estimate of $46.72 million. As a group, analysts forecast that Kamada will post 0.44 EPS for the current fiscal year.

Institutional Trading of Kamada

A number of hedge funds and other institutional investors have recently modified their holdings of KMDA. Cubist Systematic Strategies LLC acquired a new stake in shares of Kamada in the first quarter valued at approximately $206,000. NewEdge Advisors LLC grew its holdings in Kamada by 119.9% during the 1st quarter. NewEdge Advisors LLC now owns 51,661 shares of the biotechnology company’s stock worth $341,000 after acquiring an additional 28,165 shares during the period. Goldman Sachs Group Inc. acquired a new stake in Kamada during the 1st quarter worth $497,000. Jane Street Group LLC acquired a new stake in Kamada during the 1st quarter worth $582,000. Finally, Arrowstreet Capital Limited Partnership acquired a new stake in Kamada during the 2nd quarter worth $472,000. Institutional investors and hedge funds own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.